Jennison Associates
UTHR icon

Jennison Associates’s United Therapeutics UTHR Stock Holding History

Jennison Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,736
Closed -$6.6M – 630
2022
Q4 		$6.6M Buy
23,736
+21,645
+1,035% +$5.46M 0.01% 417
2022
Q3 		$438K Sell
2,091
-6,336
-75% -$1.42M ﹤0.01% 590
2022
Q2 		$1.99M Buy
+8,427
New +$1.71M ﹤0.01% 462
2014
Q1 		– Sell
-15,087
Closed -$1.71M – 784
2013
Q4 		$1.71M Sell
15,087
-1,040
-6% -$93.8K ﹤0.01% 573
2013
Q3 		$1.27M Buy
16,127
+334
+2% +$24.4K ﹤0.01% 591
2013
Q2 		$1.04M Buy
+15,793
New +$1.02M ﹤0.01% 586

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Jennison Associates's UTHR Position: Q1 2023 in Review

Jennison Associates sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 23,736 shares — an estimated $6.6M sold.

Jennison Associates first reported a position in UTHR in Q2 2013 and held it in 6 quarters. The position peaked at $6.6M in Q4 2022. 505 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

  • Jennison Associates reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Jennison Associates sold 23,736 United Therapeutics shares in Q1 2023, an estimated $6.6M.
  • Jennison Associates first reported a position in United Therapeutics in Q2 2013 and held it in 6 quarters.
  • Jennison Associates's United Therapeutics position peaked at $6.6M in Q4 2022.
  • 505 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Jennison Associates's 13F filing for Q1 2023, filed 26 Apr 2023.